Sales of Lilly's top-selling product, the diabetes treatment Mounjaro, jumped 60% to $3.53 billion in the final quarter of ...

Diabetes describes a group of metabolic diseases characterized by high blood sugar levels. Diabetes can be caused by the pancreas not producing insulin (type 1 diabetes) or by insulin resistance ...

Ozempic is approved for the management of type 2 diabetes, but it’s also used off ... Once you sign up, you can book an appointment with a board certified healthcare professional who will ...

Shares of Eli Lilly & Co. were headed for their worst ... citing slower-than-expected growth in sales of its diabetes and weight-loss drugs. “While the U.S. incretin market grew 45% compared ...

Eli Lilly and Co (Lilly) is a healthcare company that discovers, develops, and markets human healthcare products. The company offers medicines for cardiovascular conditions, diabetes, endocrinology, ...

In the literary world, this year is shaping up to be a good one for fans of cultural criticism: There are new books about Better Call Saul and biographies of James Gandolfini and Lorne Michaels on ...

After losing two of her older siblings to diabetes and getting diagnosed with it herself in 2021, Shannon Ward decided to write a children’s book about the disease and has been working to make it ...

In fact, we’re in the middle of a global shortage; those prescribed semaglutide to treat type 2 diabetes – as it ... as did Eli Lilly, the maker of Mounjaro. As those developments continue ...

At the moment, clinicians use BMI or body mass index to diagnose obesity, a calculation based on a person’s weight and height. But this tool is not precise enough and they should also take other ...

The pharmaceutical giant now projects $13.5 billion in revenue for the quarter, sparking concerns over the performance of its blockbuster weight-loss and diabetes drugs, Mounjaro and Zepbound. As of ...

Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and global expansion of sales of its diabetes and weight loss drugs should all ...